BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Research

Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS

Biogen Inc. (Nasdaq: BIIB) announced today the outcome of the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Dr...

March 23, 2023 | News

Emmes Acquires Essex Management

Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovatio...

March 22, 2023 | News

Aitia and UCB Announce Strategic Drug Discovery Collaboration in Huntington's Disease

Huntington's disease is a debilitating genetic disorder that affects the brain, causing gradual degeneration of nerve cells in specific areas of the brain,...

March 20, 2023 | News

Keymed Biosciences Advancing Clinical Progress and Global Collaboration

Development of Innovative and Differentiated Pipelines Core Product CM310 (IL-4Rα antibody): Initiated Phase III registrational cl...

March 18, 2023 | News

Glenmark's GRC 54276 IND application accepted by US FDA for first-in-human study on advanced tumors

Glenmark Specialty SA, the subsidiary of Glenmark Pharmaceuticals Ltd., an innovation-driven, global pharmaceuticals company received acceptance from the U...

March 17, 2023 | News

Mabwell begins first human trial of iron-regulating drug 9MW3011

The study (CTR20230046) is a phase 1, single center, randomized, double-blind，placebo-controlled, ascending dose study to evaluate the safety, ...

March 15, 2023 | News

Servier's Phase 3 INDIGO trial shows positive results for vorasidenib in IDH-mutant Glioma

Clinically meaningful achievement of primary and secondary endpoints is first major advance in treatment of low-grade glioma in more than 20 years Endpo...

March 15, 2023 | News

Antengene's ATG-022 Phase I CLINCH Trial for Solid Tumor Treatment Receives IND Approval in China

- Discovered and developed in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugate (ADC) targeting the Tumor Assoc...

March 14, 2023 | News

Telix's Revolutionary Kidney Cancer Imaging Study Takes Center Stage at EAU's 'Game Changing' Session

The results were featured in a "Game Changing" oral session delivered by Professor Dr. Peter Mulders from Radboud University Medical Centre (Neth...

March 14, 2023 | News

H1 Launches Advanced Diversity Insights and Clinical Trial Performance Insights

H1, the connecting force for global healthcare provider, clinical, science, and research information, today announced the availability of indication-level ...

March 13, 2023 | News

Boan Biotech Completes Patient Enrollment for Aflibercept Trial in China

Aflibercept is a homodimeric fusion protein consisting of portions of human vascular endothelial growth factor receptor (VEGFR) extracellular domains (VEGF...

March 13, 2023 | News

AnnJi Pharma and Avenue Therapeutics Enter Licensing Agreement for Clinical Asset AJ201 to Treat Kennedy's Disease.

Under the terms of the license agreement, AnnJi will receive upfront payments of $3 million and is entitled to receive future development, regula...

March 13, 2023 | News

Estrella Biopharma's ARTEMIS® T Cell Therapy EB103 IND Cleared by FDA for B-Cell Lymphomas Clinical Trial

Estrella Biopharma, Inc. ("Estrella"), a biopharmaceutical company whose mission is to harness the evolutionary power of the human immune system to transfo...

March 09, 2023 | News

Telix to Present ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline at EAU

Further data from Telix's completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (Clinic...

March 09, 2023 | News

Stay Connected